Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer

被引：34

作者：

Li, Xiaoyang ^{[1
]}

Zhang, Jian ^{[1
]}

Xie, Yuanchao ^{[1
]}

Jiang, Yuqi ^{[1
]}

Zhang Yingjie ^{[1
]}

Xu, Wenfang ^{[1
]}

机构：

[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China

来源：

CURRENT DRUG TARGETS | 2014年 / 15卷 / 06期

基金：

中国博士后科学基金; 中国国家自然科学基金;

关键词：

Combined therapy; hematologic malignancies; histone deacetylase inhibitors; monotherapy; panobinostat; solid tumors; HISTONE DEACETYLASE INHIBITOR; ANTI-ANGIOGENIC AGENTS; PHASE-I TRIAL; ORAL PANOBINOSTAT; HODGKIN LYMPHOMA; CELL-DEATH; LBH589; COMBINATION; EXPRESSION; GROWTH;

D O I：

10.2174/1389450115666140306152642

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.

引用

页码：622 / 634

页数：13

共 93 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges [J].

Atadja, Peter .

CANCER LETTERS, 2009, 280 (02) :233-241

[3]

Berenson JR, 2009, BLOOD, V114, P1855

[4] Inside HDAC with HDAC inhibitors [J].

Bertrand, Philippe .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (06) :2095-2116

[5] Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status [J].

Bhargava, Pankaj ;

Robinson, Murray O. .

CURRENT ONCOLOGY REPORTS, 2011, 13 (02) :103-111

[6]

Bhatia R, 2009, ASH ANN M, V114, P2194

[7] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors [J].

Brunetto, Andre T. ;

Ang, Joo Ern ;

Lal, Rohit ;

Olmos, David ;

Molife, L. Rhoda ;

Kristeleit, Rebecca ;

Parker, Ann ;

Casamayor, Isabel ;

Olaleye, Muyibat ;

Mais, Anna ;

Hauns, Bernhard ;

Strobel, Vera ;

Hentsch, Bernd ;

de Bono, Johann S. .

CLINICAL CANCER RESEARCH, 2013, 19 (19) :5494-5504

[8] Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia [J].

Bug, G ;

Ritter, M ;

Wassmann, B ;

Schoch, C ;

Heinzel, T ;

Schwarz, K ;

Romanski, A ;

Kramer, OH ;

Kampfmann, M ;

Hoelzer, D ;

Neubauer, A ;

Ruthardt, M ;

Ottmann, OG .

CANCER, 2005, 104 (12) :2717-2725

[9] ROMIDEPSIN FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA [J].

Campas-Moya, Clara .

DRUGS OF TODAY, 2009, 45 (11) :787-795

[10] Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy [J].

Carew, Jennifer S. ;

Giles, Francis J. ;

Nawrocki, Steffan T. .

CANCER LETTERS, 2008, 269 (01) :7-17

← 1 2 3 4 5 6 7 8 9 10 →